Mahboobeh Azadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mahboobeh Azadi has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Jamei Khosroshahi
Pediatric Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
1 shared publication - Akbar Molaei
Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
1 shared publication Alireza Kamalipour
Hamilton Glaucoma Center, Shiley Eye Institute, Department of Ophthalmology, University of California, San Diego, CA, United State
1 shared publicationAlireza Salehi
MPH Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
1 shared publication- Amir Saeed
Division of Intensive Care Unit, Department of Pediatrics, Shiraz University of Medical Sciences, Shiraz, Iran
1 shared publication Erfan Taherifard
Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
1 shared publication
Latest Publications
- Open Access
- 7 May 2023
- Published by Brieflands in Archives of Pediatric Infectious Diseases
- Vol. 11 (3)
Clinical Characteristics, Laboratory Features, and Outcomes of 151 Pediatric Patients with COVID-19 and MIS-C: A Single-center Study in the Northwest of Iran
Background: To date, multiple outbreaks of coronavirus disease 2019 (COVID-19) have been reported. Moreover, a wide spectrum of multiple organ involvements has been reported. Objectives: This study aimed to describe and compare the clinical characteristics, laboratory features, and outcomes of pediatric patients with COVID-19 and Multisystem Inflammatory Syndrome of Children (MIS-C). Methods: This cohort retrospective study was performed on patients under 18 years admitted with a diagnosis of COVID-19 and MIS-C in a pediatric referral center in the northwest of Iran from March 2020 to June 2021. This study included the data obtained from three time points, including on admission, 1 week, and 3 months after admission. Results: In this study, 151 patients with a mean age of 5.3 ± 4.1 years were enrolled, out of whom 51.7% and 48.3% were in COVID-19 and MIS-C groups, respectively. Fever was observed in 64.9% of the patients. In the third-month follow-up, there was no abnormality in the neurologic, respiratory, or gastrointestinal systems. For most patients with cardiovascular involvement, normal ventricular and valvar function, and coronary arteries were obtained in follow-up. Approximately one-third of the subjects were admitted to the pediatric intensive care unit (PICU). Neonates, those with cardiac involvement and underlying disease, were at a higher risk for PICU admission (P < 0.001). Moreover, six patients died. Conclusions: Although irreversible post-COVID-19 organ involvement is uncommon among pediatric patients, routine and preplanned follow-up programs play an important role in achieving satisfactory outcomes.
- 7 May 2023
- Published by Brieflands in Archives of Pediatric Infectious Diseases
- Vol. 11 (3)
Open AccessClinical Characteristics, Laboratory Features, and Outcomes of 151 Pediatric Patients with COVID-19 and MIS-C: A Single-center Study in the Northwest of Iran
Background: To date, multiple outbreaks of coronavirus disease 2019 (COVID-19) have been reported. Moreover, a wide spectrum of multiple organ involvements has been reported. Objectives: This study aimed to describe and compare the clinical characteristics, laboratory features, and outcomes of pediatric patients with COVID-19 and Multisystem Inflammatory Syndrome of Children (MIS-C). Methods: This cohort retrospective study was performed on patients under 18 years admitted with a diagnosis of COVID-19 and MIS-C in a pediatric referral center in the northwest of Iran from March 2020 to June 2021. This study included the data obtained from three time points, including on admission, 1 week, and 3 months after admission. Results: In this study, 151 patients with a mean age of 5.3 ± 4.1 years were enrolled, out of whom 51.7% and 48.3% were in COVID-19 and MIS-C groups, respectively. Fever was observed in 64.9% of the patients. In the third-month follow-up, there was no abnormality in the neurologic, respiratory, or gastrointestinal systems. For most patients with cardiovascular involvement, normal ventricular and valvar function, and coronary arteries were obtained in follow-up. Approximately one-third of the subjects were admitted to the pediatric intensive care unit (PICU). Neonates, those with cardiac involvement and underlying disease, were at a higher risk for PICU admission (P < 0.001). Moreover, six patients died. Conclusions: Although irreversible post-COVID-19 organ involvement is uncommon among pediatric patients, routine and preplanned follow-up programs play an important role in achieving satisfactory outcomes.
- Open Access
- 1 September 2021
- Published by Maad Rayan Publishing Company in International Journal of Infectious Diseases
- Vol. 24 (9) , 657-664
Prevalence, Pattern, and Correlates of Polypharmacy among Iranian Type II Diabetic Patients: Results from Pars Cohort Study
Background: Polypharmacy can negatively affect the life of type 2 diabetes (T2DM) patients. There is little evidence on the associated factors of, and patterns of polypharmacy among T2DM patients in developing regions. The aim of this study is to determine the population-based prevalence of polypharmacy, its associated factors, and pattern in southern Iran. Methods: We used baseline data from the Pars Cohort Study (PCS). Age-standardized prevalence of polypharmacy and its 95% confidence interval (CI) were estimated. Association of polypharmacy with demographic and socio-economic factors, anthropometric measures, serum biomarkers, physical activity, cigarette and tobacco smoking, and multimorbidity was assessed by applying multivariable Poisson modeling. Prevalence ratio (PR) and its CI were estimated. The Anatomical Therapeutic Chemical (ATC) classification system was used for drug classification. Results: Totally, 874 previously diagnosed T2DM patients with a mean age of 56.3±9.2 participated in the study. The estimated age-standardized prevalence for men and women was 17.2% (CI: 12.0–22.0) and 34.1% (CI: 33.2–39.4), respectively. The prevalence of hypertension, hyperlipidemia and cardiovascular disorders among the study population was 39%, 58% and 20%, respectively. Having more than four comorbidities (PR, 3.90; CI, 2.39–6.34), central obesity (PR, 2.66; CI, 1.03–6.84), and female gender (PR, 1.49; CI, 1.14–1.97) were associated with polypharmacy. Also, 56.0% of patients and 23.0% of elder patients (>59 years old) reported using anti-diabetic agents. Conclusion: Polypharmacy was low among T2DM patients. More than 75% of the elder population were not on anti-diabetic medications. Polypharmacy was higher among patients with multiple comorbidities, central obesity, lower physical activity, lower socio-economic status, younger age at diagnosis, and longer duration of T2DM.
- 1 September 2021
- Published by Maad Rayan Publishing Company in International Journal of Infectious Diseases
- Vol. 24 (9) , 657-664
Open AccessPrevalence, Pattern, and Correlates of Polypharmacy among Iranian Type II Diabetic Patients: Results from Pars Cohort Study
Background: Polypharmacy can negatively affect the life of type 2 diabetes (T2DM) patients. There is little evidence on the associated factors of, and patterns of polypharmacy among T2DM patients in developing regions. The aim of this study is to determine the population-based prevalence of polypharmacy, its associated factors, and pattern in southern Iran. Methods: We used baseline data from the Pars Cohort Study (PCS). Age-standardized prevalence of polypharmacy and its 95% confidence interval (CI) were estimated. Association of polypharmacy with demographic and socio-economic factors, anthropometric measures, serum biomarkers, physical activity, cigarette and tobacco smoking, and multimorbidity was assessed by applying multivariable Poisson modeling. Prevalence ratio (PR) and its CI were estimated. The Anatomical Therapeutic Chemical (ATC) classification system was used for drug classification. Results: Totally, 874 previously diagnosed T2DM patients with a mean age of 56.3±9.2 participated in the study. The estimated age-standardized prevalence for men and women was 17.2% (CI: 12.0–22.0) and 34.1% (CI: 33.2–39.4), respectively. The prevalence of hypertension, hyperlipidemia and cardiovascular disorders among the study population was 39%, 58% and 20%, respectively. Having more than four comorbidities (PR, 3.90; CI, 2.39–6.34), central obesity (PR, 2.66; CI, 1.03–6.84), and female gender (PR, 1.49; CI, 1.14–1.97) were associated with polypharmacy. Also, 56.0% of patients and 23.0% of elder patients (>59 years old) reported using anti-diabetic agents. Conclusion: Polypharmacy was low among T2DM patients. More than 75% of the elder population were not on anti-diabetic medications. Polypharmacy was higher among patients with multiple comorbidities, central obesity, lower physical activity, lower socio-economic status, younger age at diagnosis, and longer duration of T2DM.